NCT02609945View on ClinicalTrials.gov

Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

April 30, 2016

Conditions
Migraine
Interventions
DRUG

zolmitriptan

Oral Tablet and Nasal Spray

DRUG

CVT-427 (zolmitriptan inhalation powder),

Capsules containing zolmitriptan; dose levels equivalent to estimated fine particle dose (i.e., lung-delivered) zolmitriptan.

Trial Locations (2)

32117

Site 001, Daytona Beach

75247

Site 002, Dallas

Sponsors
All Listed Sponsors
lead

Acorda Therapeutics

INDUSTRY

NCT02609945 - Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults | Biotech Hunter | Biotech Hunter